Insider Sell: NRX Pharmaceuticals
5:46PM ET 8/02/2022 MT NewswiresDaniel C. Javitt, 10% Owner, on July 29, 2022, sold 784,063 shares in NRX Pharmaceuticals (NRXP) for $791,433. Following the Form 4 filing with the SEC,...
Quotes Snapshot > NRXP
NRX Pharmaceuticals Inc NRXP:NASDAQ
Last Price$0.71NASDAQ Closing Price as of 4:00PM ET 8/19/22
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change-0.03(3.65%)
Bid (Size)$0.70 (10)
Ask (Size)$0.74 (4)
Day Low / High$0.70 - 0.75
Volume462.5 K
Read more news Recent News
NRX Pharmaceuticals Names Stephen Willard CEO
7:41AM ET 7/13/2022 MT NewswiresNRX Pharmaceuticals (NRXP) said Wednesday it has named Stephen Willard chief executive officer, and a member of the company's board of directors. Willard...
NRx Pharmaceuticals Says FDA Declines Emergency Use Authorization for COVID-19-Driven Respiratory Failure Therapy
7:59AM ET 7/01/2022 MT NewswiresNRx Pharmaceuticals (NRXP) said Friday the US Food and Drug Administration declined to approve its aviptadil therapy for emergency use authorization. The...
--HC Wainwright Starts NRX Pharmaceuticals at Buy With $2 Price Target
6:22AM ET 6/30/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
View all Commentary and Analysis
NRx Pharmaceuticals, Inc. (NRXP) CEO Stephen Willard on Q2 2022 Results - Earnings Call Transcript
12:51PM ET 8/15/2022 Seeking AlphaNRx Pharmaceuticals, Inc. (NRXP) CEO Robert Besthof on Q1 2022 Results - Earnings Call Transcript
11:05AM ET 5/16/2022 Seeking AlphaNRx Pharmaceuticals, Inc. (NRXP) CEO Robert Besthof on Q4 2021 Results - Earnings Call Transcript
5:19PM ET 3/31/2022 Seeking AlphaNRx Pharmaceuticals: Potential For First In Bipolar Depression Suicidal Ideation Treatment, Along As Covid-19 Play
10:37AM ET 2/23/2022 Seeking AlphaCompany Profile
Business DescriptionNRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE. View company web site for more details
| Address | 1201 Orange Street Wilmington, Delaware 19801 |
| Phone | +1.484.254.6134 |
| Number of Employees | N/A |
| Recent SEC Filing | 08/15/2022 10-Q |
| Chief Executive Officer & Director | Stephen H. Willard |
| Chief Commercial Officer & Head-Operations | Robert Besthof |
| Chief Financial Officer & Treasurer | Seth L. van Voorhees |
| Chief Strategy Officer | Dennis K. McBride |
Company Highlights
| Price Open | $0.73 |
| Previous Close | $0.74 |
| 52 Week Range | $0.49 - 16.99 |
| Market Capitalization | $48.2 M |
| Shares Outstanding | 67.6 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 11/15/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$7.95 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -736.15% |
Analyst Ratings as of 06/29/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |